Researchers from Australia paired the tumour-specific radiation sensitizer idronoxil (NOX66) with 177Lu-PSMA-617 (LuPIN) with the hope to improve outcomes in heavily treated mCRPC. The gene discussed is FOLH1; the disease is neoplasm.